The firm is also studying PTG-007 in patients with early-stage type 1 diabetes, but is looking for a partner for the pivotal trial.

AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy programme, as per an 18 ...

Achievement of first significant research milestone triggers an option exercise payment of $10 million from AstraZenecaAstraZeneca will progress ...

Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) ...

This is the first significant research milestone achieved under its 2023 collaboration agreement with AstraZeneca to develop, manufacture and commercialize autologous, engineered Treg cell ...

Quell’s Treg platform induces sustained expression of FOXP3. Image credit: Shutterstock/ Vink Fan. AstraZeneca has exercised an option to license a cell therapy from Quell Therapeutics, resulting in a ...

Keywords: Treg, cell therapy, specificity, functionality, stability, manufacturing, biomarker, clinical trial, regulatory, safety, combination Important Note: All contributions to this Research Topic ...

Astrazeneca plc has selected a candidate to progress under its type 1 diabetes regulatory T cell (Treg) therapy program with Quell Therapeutics Ltd. The company has exercised its exclusive option to ...